Navigation Links
Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the malignant melanoma therapy market will experience robust annual growth of more than 11 percent from 2012 to 2022 in the world's major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Immunotherapies will continue to dominate the malignant melanoma market through 2022. Sales for this drug class will increase dramatically during this period owing primarily to the anticipated launches of the immune checkpoint inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, for treatment of unresectable and metastatic melanoma and the anticipated adjuvant line-extension of Bristol-Myers Squibb's Yervoy. In 2022, sales of immunotherapies for melanoma will total more than $2.1 billion with sales of immune checkpoint inhibitors accounting for the vast majority of these sales.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor report entitled Malignant Melanoma finds that the BRAF/MEK inhibitor drug class will continue to play an important role in treatment of BRAF V600-mutation-positive unresectable and metastatic melanoma and that BRAF/MEK inhibitor combination therapy will become the preferred treatment approach over BRAF and MEK inhibitor monotherapy owing to its anticipated improved efficacy and safety and tolerability compared with monotherapy treatment. By 2022, three BRAF/MEK inhibitor combination therapies will launch, the first of which will be GlaxoSmithKline's Tafinlar/Mekinist, in 2014, in the United States and Europe. All BRAF/MEK inhibitor combination therapies will compete for market share in the unresectable/metastatic BRAF V600-mutation-positive patient population, with sales of this drug class accounting for one-fifth of the total market in 2022.

The report also finds that, despite the anticipated launch of several novel premium-priced therapies during the 2012-2022 forecast period, Yervoy will remain the sales leader through 2022 due to the agent's high price, its anticipated line-extension into the adjuvant setting and its anticipated first-line use in combination with nivolumab for unresectable/metastatic disease.

"When considering the melanoma clinical development pipeline, interviewed thought leaders are most excited about the immune checkpoint inhibitors," said Decision Resources Senior Business Insights Analyst, Karen Pomeranz, Ph.D. "We forecast that nivolumab and MK-3475 will launch for treatment of melanoma in all markets under study, attaining their highest sales in the first-line unresectable/metastatic setting. In 2022, nivolumab and MK-3475 will earn overall major market sales of nearly $1.1 billion."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
2. CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
3. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
4. Economic Growth Continues In 2014; Manufacturing Growth Expected in 2014; Revenue to Increase 4.4%; Capital Expenditures to Increase 8.0%; Capacity Utilization Currently at 80.3%; Non-Manufacturing Growth Projected in 2014; Revenue to Increase 3.6%;
5. Widespread Acceptance and Use of Accurays Technologies Continue to Grow
6. ResMed Receives Injunctions against APEX and BMC in Germany, Continues Enforcement of Patents in Europe
7. STAAR Surgical Reports Continued Momentum During Third Quarter
8. Grant from Smith & Nephew Helps Continue Educational Activities for Podiatric Surgeons
9. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
10. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
11. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... -- Memorial Hermann Health System has teamed up with Houston ... a one-of-a-kind experience to pediatric patients at Children,s ... 360-degree video and Google Cardboard, Howard was able to ... the patients and their families an unexpected, and energetically ... video . Memorial Hermann IRONMAN Sports ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... With FCPX Overlay Embers from Pixel Film Studios users can now apply ... user can select from up to 40 effect overlays. With FCPX Overlay Embers users ... value, contrast, glow, and more all within a click of a mouse. , ...
(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mystic Buddha Publishing House presents Valentine’s ... Buddha, the biography of Rama - Dr. Frederick Lenz. , According to ... of a Buddhist teacher for teaching and helping others. Valentine’s Day celebrates love ...
(Date:2/12/2016)... ... ... , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – 12:30 p.m. ... learn from history are doomed to repeat it.” , An analysis of CDRH’s enforcement actions ... takes time. , Take a close look at the warning letters the agency sent ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
Breaking Medicine News(10 mins):